SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories
Dr Reddys Laboratories
BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Dec 18, 16:00
3150.50
-9.95 (-0.31%)
VOLUME 70,141
LIVE
NSE
Dec 18, 15:59
3151.25
-9.1 (-0.29%)
VOLUME 351,199
Management Interviews on Dr Reddys Laboratories
Select Year: 2013 |  2012 |  2011 | 2010 | 2009 | 2008 | 2007 | 2000-2006
Ranbaxy loses Valcyte exclusivity: An analysis 

10.14 am | 07 Nov 2014 |  Source: CNBC-TV18

Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche...

Likely to file 2 NDAs worth $100 m each soon: Dr Reddy's 

4.51 pm | 29 Oct 2014 |  Source: CNBC-TV18

Discussing the company’s results, GV Prasad co-chairman and CEO, DRL, said the quarter has been a flattish one on the back of high R&D expenses. He ...

1
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.